Metformin is a Phase II study that examines the cognitive effects of the diabetes drug Metformin on non-diabetic individuals.

Those with mild cognitive impairment (MCI) or early Alzheimer’s disease may be eligible. The study consists of one baseline visit, five in-clinic visits (one per month for five consecutive months), and twelve weekly phone calls.

Download a one-page overview of the study including contact information